BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a strong sell rating to a sell rating in a report released on Friday morning.
Several other research firms have also recently issued reports on BIOS. Canaccord Genuity assumed coverage on BioScrip in a research report on Wednesday, December 12th. They set a buy rating and a $5.00 target price for the company. TheStreet upgraded BioScrip from a d+ rating to a c- rating in a research report on Monday, November 26th. Lake Street Capital increased their target price on BioScrip from $4.50 to $10.00 and gave the stock a buy rating in a research report on Friday, December 7th. Finally, Zacks Investment Research cut BioScrip from a hold rating to a sell rating in a research report on Thursday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $4.70.
NASDAQ BIOS opened at $2.34 on Friday. BioScrip has a 52 week low of $2.29 and a 52 week high of $4.14. The stock has a market capitalization of $355.95 million, a PE ratio of -5.32 and a beta of 0.76.
Large investors have recently added to or reduced their stakes in the stock. Maven Securities LTD purchased a new position in BioScrip during the 4th quarter valued at approximately $45,000. Caxton Associates LP purchased a new position in BioScrip during the 4th quarter valued at approximately $52,000. Virtu Financial LLC grew its holdings in BioScrip by 60.6% during the 4th quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after buying an additional 6,868 shares in the last quarter. Menta Capital LLC purchased a new position in BioScrip during the 4th quarter valued at approximately $124,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in BioScrip by 383.3% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $161,000 after buying an additional 35,700 shares in the last quarter. Hedge funds and other institutional investors own 82.61% of the company’s stock.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Recommended Story: How Buying a Call Option Works
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.